Agent orange exposure and prostate cancer risk in the million veteran program

Autor: Meghana S. Pagadala, Asona J. Lui, Allison Y. Zhong, Julie A. Lynch, Roshan Karunamuni, Kyung Min Lee, Anna Plym, Brent S. Rose, Hannah K. Carter, Adam S. Kibel, Scott L. DuVall, J. Michael Gaziano, Matthew S. Panizzon, Richard L. Hauger, Tyler M. Seibert

Publikováno v: Acta Oncologica, Vol 63, Iss 1 (2024)

Background: The US government considers veterans to have been exposed to Agent Orange if they served in Vietnam while the carcinogen was in use, and these veterans are often deemed at high risk of prostate cancer (PCa). Here, we assess whether presum

Externí odkaz: https://doaj.org/article/4271ec4c5c6742b9ac52d13f2ba0e5ce

Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysisResearch in context

Autor: James Yarmolinsky, Jamie W. Robinson, Daniela Mariosa, Ville Karhunen, Jian Huang, Niki Dimou, Neil Murphy, Kimberley Burrows, Emmanouil Bouras, Karl Smith-Byrne, Sarah J. Lewis, Tessel E. Galesloot, Lambertus A. Kiemeney, Sita Vermeulen, Paul Martin, Demetrius Albanes, Lifang Hou, Polly A. Newcomb, Emily White, Alicja Wolk, Anna H. Wu, Loïc Le Marchand, Amanda I. Phipps, Daniel D. Buchanan, Sizheng Steven Zhao, Dipender Gill, Stephen J. Chanock, Mark P. Purdue, George Davey Smith, Paul Brennan, Karl-Heinz Herzig, Marjo-Riitta Järvelin, Chris I. Amos, Rayjean J. Hung, Abbas Dehghan, Mattias Johansson, Marc J. Gunter, Kostas K. Tsilidis, Richard M. Martin, Maria Teresa Landi, Victoria Stevens, Ying Wang, Demetrios Albanes, Neil Caporaso, Christopher I. Amos, Sanjay Shete, Heike Bickeböller, Angela Risch, Richard Houlston, Stephen Lam, Adonina Tardon, Chu Chen, Stig E. Bojesen, H-Erich Wichmann, David Christiani, Gadi Rennert, Susanne Arnold, John K. Field, Loic Le Marchand, Olle Melander, Hans Brunnström, Geoffrey Liu, Angeline Andrew, Hongbing Shen, Shan Zienolddiny, Kjell Grankvist, Mikael Johansson, M. Dawn Teare, Yun-Chul Hong, Jian-Min Yuan, Philip Lazarus, Matthew B. Schabath, Melinda C. Aldrich, Rosalind A. Eeles, Christopher A. Haiman, Zsofia Kote-Jarai, Fredrick R. Schumacher, Sara Benlloch, Ali Amin Al Olama, Kenneth R. Muir, Sonja I. Berndt, David V. Conti, Fredrik Wiklund, Stephen Chanock, Catherine M. Tangen, Jyotsna Batra, Judith A. Clements, Henrik Grönberg, Nora Pashayan, Johanna Schleutker, Stephanie J. Weinstein, Catharine M.L. West, Lorelei A. Mucci, Géraldine Cancel-Tassin, Stella Koutros, Karina Dalsgaard Sørensen, Eli Marie Grindedal, David E. Neal, Freddie C. Hamdy, Jenny L. Donovan, Ruth C. Travis, Robert J. Hamilton, Sue Ann Ingles, Barry S. Rosenstein, Yong-Jie Lu, Graham G. Giles, Robert J. MacInnis, Adam S. Kibel, Ana Vega, Manolis Kogevinas, Kathryn L. Penney, Jong Y. Park, Janet L. Stanfrod, Cezary Cybulski, Børge G. Nordestgaard, Sune F. Nielsen, Hermann Brenner, Christiane Maier, Christopher J. Logothetis, Esther M. John, Manuel R. Teixeira, Susan L. Neuhausen, Kim De Ruyck, Azad Razack, Lisa F. Newcomb, Davor Lessel, Radka Kaneva, Nawaid Usmani, Frank Claessens, Paul A. Townsend, Jose Esteban Castelao, Monique J. Roobol, Florence Menegaux, Kay-Tee Khaw, Lisa Cannon-Albright, Hardev Pandha, Stephen N. Thibodeau, David J. Hunter, Peter Kraft, William J. Blot, Elio Riboli

Publikováno v: EBioMedicine, Vol 100, Iss , Pp 104991- (2024)

Summary: Background: Tumour-promoting inflammation is a “hallmark” of cancer and conventional epidemiological studies have reported links between various inflammatory markers and cancer risk. The causal nature of these relationships and, thus, th

Externí odkaz: https://doaj.org/article/76559893532a492cbb3d1275b22f7ce4

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

Autor: Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsofia Sztupinszki, Antoine Simoneau, Ning Xie, Ladan Fazli, Xuesen Dong, Haruhito Azuma, Atish D. Choudhury, Kent W. Mouw, Zoltan Szallasi, Lee Zou, Adam S. Kibel, Li Jia

Publikováno v: Nature Communications, Vol 14, Iss 1, Pp 1-19 (2023)

Identifying prostate cancer patients who may respond well to PARP inhibitors is important for their success in the clinic. Here, using a genome-wide CRISPR-Cas9 knockout screen, the authors identify MMS22L as a biomarker for sensitivity to PARP inhib

Externí odkaz: https://doaj.org/article/ae5f553e58e5416b821643fde0923364

Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study.

Autor: Milena Braga-Basaria, Thomas G Travison, Mary-Ellen Taplin, Alexander Lin, Alyssa B Dufour, Daniel Habtemariam, Paul L Nguyen, Adam S Kibel, Praful Ravi, Richelle Bearup, Hannah Kackley, Hussein Kafel, Kieran Reid, Thomas Storer, Donald C Simonson, Marie McDonnell, Shehzad Basaria

Publikováno v: PLoS ONE, Vol 18, Iss 2, p e0281508 (2023)

Androgen deprivation therapy (ADT), a cornerstone of treatment for patients with locally advanced and metastatic prostate cancer, is associated with many adverse effects, including osteoporosis, sexual dysfunction, fatigue, and vasomotor symptoms. It

Externí odkaz: https://doaj.org/article/4cf46102272e4122abe95a4588531750

Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations

Autor: Fei Chen, Burcu F Darst, Ravi K Madduri, Alex A Rodriguez, Xin Sheng, Christopher T Rentsch, Caroline Andrews, Wei Tang, Adam S Kibel, Anna Plym, Kelly Cho, Mohamed Jalloh, Serigne Magueye Gueye, Lamine Niang, Olufemi J Ogunbiyi, Olufemi Popoola, Akindele O Adebiyi, Oseremen I Aisuodionoe-Shadrach, Hafees O Ajibola, Mustapha A Jamda, Olabode P Oluwole, Maxwell Nwegbu, Ben Adusei, Sunny Mante, Afua Darkwa-Abrahams, James E Mensah, Andrew Anthony Adjei, Halimatou Diop, Joseph Lachance, Timothy R Rebbeck, Stefan Ambs, J Michael Gaziano, Amy C Justice, David V Conti, Christopher A Haiman

Publikováno v: eLife, Vol 11 (2022)

Background: We recently developed a multi-ancestry polygenic risk score (PRS) that effectively stratifies prostate cancer risk across populations. In this study, we validated the performance of the PRS in the multi-ancestry Million Veteran Program an

Externí odkaz: https://doaj.org/article/357704951c834856af7fc63a759e4c2d